Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion

作     者：Yuan-Yuan Zhong Chong Tang Lan-Yue Zhang Xue-Dong Zhang Shu-Lin Liu 

作者机构：The First Affiliated Hospital of Chongqing Medical UniversityChongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye DiseasesChongqing 400016China 

出 版 物：《International Journal of Ophthalmology(English edition)》 (国际眼科杂志（英文版）)

年 卷 期：2024年第17卷第10期

页      面：1837-1842页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：Supported by the National Natural Science Found of China(No.81870673 No.81800814 No.82201168) 

主　　题：macular edema dexamethasone implant anti-vascular endothelial growth factor retinal vein occlusion diabetic retinopathy 

摘      要：AIM:To evaluate the efficacy,timing of retreatment and safety of dexamethasone(DEX)implant on macular edema(ME)secondary to diabetic retinopathy(DME)and retinal vein occlusion(RVO-ME)patients who were refractory to anti-vascular endothelial growth factor(VEGF)***:This retrospective study included 37 eyes received at least one DEX implant treatment for DME or RVO-ME between January 1,2019,and January 1,*** refractory DME and RVO-ME cases received at least 5 anti-VEGF injections and failure to gain more than 5 letters or a significant reduction in central retinal thickness(CRT).The best corrected visual acuity(BCVA)and CRT were measured at baseline,and at 1,3,4 and 6mo post-DEX implant *** events such as elevated intraocular pressure(IOP)and cataract were ***:For RVO cases(n=22),there was a significant increase in BCVA from 0.27±0.19 to 0.35±0.20 at 6mo post-DEX injection(P0.05)and CRT decreased from 472.1±90.6 to 240.5±39.0μm at 6mo(P0.0001).DME cases(n=15)experienced an improvement in BCVA from 0.26±0.15 to 0.43±0.20 at 6mo post-DEX implant injection(P=0.0098),with CRT reducing from 445.7±55.7 to 271.7±34.1μm at 6mo(P0.0001).Elevated IOP occurred in 45.9% of patients but was well-controlled with topical *** cases of cataract or other adverse events were ***:DEX implants effectively improve BCVA and reduce CRT in refractory DME and *** research with larger cohorts and longer follow-up periods is needed to confirm these findings and assess long-term outcomes.